Updated Sunday, September 23, 2018
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Integrative Medicine: Volume 16, 2018   Issue 1,  Pages: 45-50

DOI: 10.1016/j.joim.2017.12.007
Original Clinical Research
Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: a double-blind placebo-controlled randomized clinical trial
1. Zahra Hajmohammadi (Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
2. Mojtaba Heydaria (Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
3. Majid Nimrouzi (Department of Traditional Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
4. Pouya Faridi (Department of Phytopharmaceuticals, School of Pharmacy and Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
5. Mohammad Javad Zibaeenezhad (Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
6. Gholamhossein Ranjbar Omrani (Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran )
7. Mesbah Sham (Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 98713, Iran )

Abstract

Background
Lipid-lowering effect of Rhus coriaria L. (Rhus) has been investigated in multiple animal studies with promising results. Nonetheless, its clinical efficacy has not been adequately examined.
Objective
The aim of this study was to evaluate the lipid-lowering effects of Rhus among patients with hyperlipidemia.
Design, setting, participants and interventions
The study was designed as a two-arm, double-blind placebo-controlled randomized clinical trial, using a parallel design. Eighty patients with primary hyperlipidemia were randomly assigned to receive
Rhus capsules or placebo for 6?weeks.
Main outcome measures
The serum lipid levels, apolipoprotein-A1 (Apo-A1) and apolipoprotein-B (Apo-B) were measured.
Results
Mean serum high-density lipoprotein cholesterol (HDL-C) and Apo-A1 levels were significantly increased in the
Rhus group, compared with the placebo group, after 6?weeks of intervention (P?=?0.001). The analysis of covariance test including age, gender, body mass index (BMI), and smoking as co-variables revealed that the increase in HDL-C and Apo-A1 levels remained significant, and increases in HDL-C were dependent on the increase in Apo-A1 levels. No significant difference was observed between Rhus and placebo groups in terms of mean reductions in total cholesterol, low-density lipoprotein cholesterol and triglyceride levels; however, more significant improvement was observed among obese patients (BMI?≥?30?kg/m2).
Conclusion
The study showed significant increases in HDL-C and Apo-A1 levels in response to Rhus supplementation in patients with hyperlipidemia.
Trial registration
ClinicalTrials.gov ID: NCT02295293.

 

Welcome to JIM! You are the number 979 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Hajmohammadi Z, Heydari M, Nimrouzi M, Faridi P, Zibaeenezhad MJ, Omrani GR, Sham M. Rhus coriaria L. increases serum apolipoprotein-A1 and high-density lipoprotein cholesterol levels: a double-blind placebo-controlled randomized clinical trial. J Integr Med. 2017 December; Epub ahead of print.
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号